Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» LDK378
LDK378
Novartis races to the FDA with its 'breakthrough' lung cancer drug
Fierce Biotech
Wed, 01/29/14 - 10:24 am
Novartis
non-small cell lung cancer
LDK378
FDA
breakthrough therapies
5 Experimental Drugs That Could Make a Big Difference in Treating Lung Cancer
Motley Fool
Sun, 09/22/13 - 11:23 am
LDK378
Novartis
bavituximab
Peregrine Pharmaceuticals
nivolumab
Bristol-Myers Squibb
lambrolizumab
Merck
lung cancer
CO-1686
Clovis Oncology
These 2 Companies Are the Biggest Winners of the FDA's Breakthrough Designation
Motley Fool
Tue, 09/3/13 - 09:33 am
FDA
breakthrough therapies
ibrutinib
Pharmacyclics
JNJ
Novartis
LDK378
serelaxin
daratumumab
Genmab
What Does The FDA's Breakthrough Designation Mean For Investors?
Seeking Alpha
Mon, 08/26/13 - 01:28 pm
FDA
breakthrough therapies
AbbVie
Alexion
Ariad Pharmaceuticals
Biomarin
Bristol-Myers Squibb
SynaGeva BioPharma
GSK
JNJ
Merck
Novartis
Pharmacyclics
Pfizer
Vertex Pharmaceuticals
daratumumab
ibrutinib
Kalydeco
lambrolizumab
palbociclib
LDK378
SD-101
obinutuzumab
serelaxin
asfotase alfa
bimagrumab
drisapersen
sebelipase alfa
These 2 Health Care Stocks Could Win Big With FDA's New 'Breakthrough' Status
Yahoo/Street Authority
Fri, 06/14/13 - 12:21 pm
FDA
breakthrough therapies
LDK378
Novartis
palbociclib
Pfizer
lambrolizumab
Merck
Novartis Boost Seen in Fast Approvals as Protection Ends
Bloomberg
Mon, 05/6/13 - 09:08 am
drug approvals
Novartis
LDK378
lung cancer
FDA seeks to fast track Novartis lung cancer drug
Reuters
Fri, 03/15/13 - 11:10 am
FDA
fast track
Novartis
non-small cell lung cancer
LDK378